

Datasheet: HCA305 BATCH NUMBER 158430

Description: HUMAN ANTI RANIBIZUM	
Specificity:	RANIBIZUMAB
Other names:	Lucentis
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD16746_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Αŗ	pl	ica	tio	ns

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Not Determined	Suggested Dilution
ELISA •		

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein	

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Ranibizumab

Specificity

Human Anti-Ranibizumab Antibody, clone AbD16746_hlgG1 is a paratope specific,

inhibitory anti-idiotypic antibody in IgG1 format that recognizes the monoclonal antibody drug ranibizumab. The antibody does not recognize recombinant human vascular endothelial growth factor A (VEGF-A) or ranibizumab when in complex with recombinant human VEGF-A.

Clone AbD16746_hlgG1 is a fully human recombinant monoclonal antibody with lgG1 isotype and is suitable as a control or calibration standard in an anti-drug antibody (ADA) assay.

This antibody also recognizes the monoclonal antibody drug bevacizumab.

Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.

View a summary of all anti-ranibizumab antibodies

Affinity	The monovalent intrinsic affinity of AbD16746_hlgG1 was measured as K_D = 2 nM by real time, label free molecular interaction analysis on immobilized bevacizumab.
ELISA	Clone AbD16746_hlgG1 can be used in a direct or indirect ELISA or as a calibrator for the set-up of an anti-drug antibody assay.
	Protocol: ADA bridging ELISA
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
	Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA305 10094

Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.	
Regulatory	For research purposes only	
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>	

Related Products

Recommended Useful Reagents

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)
HISPEC ASSAY DILUENT (BUF049A)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M382286:210512'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint